Esperion Therapeutics (ESPR) Weakness Overdone Amid FDA AdCom on SNY/REGN's Praluent, UBS Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq reaches record high close, AI stocks rally
- Meta AI agent triggers heavy selloff in banks, insurers, and travel stocks
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Esperion Therapeutics (ESPR) Has Notable New Fan at the FDA and Should Be Bought on Weakness - Barclays
June 11, 2015 2:21 PM EDTAfter losing 19% Wednesday amid labeling and other concerns arising from the PCSK9 FDA AdCom panel discussion, weakness in Esperion Therapeutics (NASDAQ: ESPR) is continuing today with stock off another 2.6%. Despite the weak stock action, many sell-side analysts have come out to defend the name. Barclays was the latest, and today brought with... More
Credit Suisse Defends Esperion Therapeutics (ESPR); Does Not See Impact from PCSK9 Panel
June 10, 2015 1:06 PM EDTCredit Suisse is the latest firm to come out in defense of Esperion Therapeutics (NASDAQ: ESPR), which fell more than 20% today following the PCSK9 panel discussion yesterday, which some viewed as cautious for the label.
Analyst Jeremiah Shepard said they do not... More
Alirocumab AdComm Net Positive for Esperion Therapeutics (ESPR) ETC-1002, Needham & Company Says
June 10, 2015 8:15 AM EDTNeedham & Company analyst Chad Messer reiterated a Buy rating and $130 price target on Esperion Therapeutics (NASDAQ: ESPR) following a read-through from Alirocumab AdComm, which they view as a net positive for ETC-1002.
Messer commented, "We walked away from the FDA advisory panel for... More
Esperion (ESPR), Amgen (AMGN) Shares Weaken Post-Market After Praluent Gets FDA Backing
June 9, 2015 5:39 PM EDT(Updated - June 9, 2015 5:49 PM EDT)
Esperion Therapeutics (NASDAQ: ESPR) shares declined after-hours Tuesday. Earlier an FDA panel voted to back Regeneron (NASDAQ: REGN) and Sanofi's (NYSE: SNY) PCSK9, Praluent. Shares of Amgen (NASDAQ: AMGN) are also trading down slightly.
... More